Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Clare F. Malone(Arup Group (United States)), Kimberly Stegmaier(Broad Institute), John M. Hatcher(Harvard University), Amy Saur Conway(Dana-Farber Cancer Institute), Delan Khalid(Dana-Farber Cancer Institute), Nathanael S. Gray(Stanford University), Gabriela Alexe(Broad Institute), Amanda L. Robichaud(Dana-Farber Cancer Institute), Alexandra B. Forman(Broad Institute), Amy Goodale(Broad Institute), Kathleen Engel(Broad Institute), Minjee Kim(Massachusetts Eye and Ear Infirmary), Federica Piccioni(Broad Institute), Allen Thayakumar(Dana-Farber Cancer Institute), Ashleigh Meyer(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
|Cancer Discovery|2016|632